

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG)
OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that JMT108 (the “**Product**”), a new Class I bi-functional fusion protein drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product has also obtained approval from the National Medical Products Administration of the People’s Republic of China in March 2025 to conduct clinical trials in China.

The Product is a recombinant fully human anti-PD-1/IL-15 bi-functional fusion protein, which relieves immunosuppression on PD-1 positive tumor infiltrating immune cells caused by the interaction of PD-1 and PD-L1, and further promotes the proliferation and activation of related immune cells through PD-1 antibody binding-dependent activation of the IL-15 downstream signaling pathway, thereby achieving enhanced anti-tumor efficacy. The indication for this approval is advanced malignant tumors. Preclinical studies demonstrated that the Product had a broad variety of indications with significant anti-tumor effects and a good safety profile in multiple malignant tumor models, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 8 April 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.